▲ +14.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $128.64, with a high forecast of $170.00 and a low forecast of $89.00. The average price target represents a 14.58% upside from the last price of $112.27.
The current consensus among 12 polled investment analysts is to hold stock in Kodiak Sciences. This rating has held steady since January 2020, when it changed from a Buy consensus rating.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.